TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02607410
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Study: NCT00703885
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Study: NCT02625090
Drug: UCB0942
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral
Study: NCT02423538
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets (1 mg, 5 mg, 10 mg)
Study: NCT02423538
Drug: SHR0302 placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
Study: NCT02615119
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
Study: NCT03215381
Drug: [11C]AZD1390
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\]AZD1390
Study: NCT03685084
Drug: AAI101 i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
Study: NCT03685084
Drug: Saline 0.9% infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle infusion
Study: NCT00629499
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 of IV cyclophosphamide
Study: NCT02730572
Drug: Concerta AG formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
Study: NCT02730572
Drug: Concerta EG formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
Study: NCT04105998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04105959
Drug: RIST4721
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST4721 oral solution
Study: NCT04105959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT02243683
Drug: AX-024.HCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542126
Drug: Decapeptyl 0.1 mg after embryo transfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
Study: NCT02311881
Drug: Paracetamol 1000 mg SR tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
Study: NCT02311881
Drug: Paracetamol 665 mg SR tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
Study: NCT02311881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
Study: NCT04704713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00550186
Drug: HaemoHES 6%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00252330
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02776605
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
Study: NCT02776605
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
Study: NCT02776605
Drug: ARA-C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
Study: NCT01484496
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Study: NCT03773302
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Study: NCT02478242
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02735551
Drug: Long Acting Reversible Contraception (LARC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
Study: NCT04388215
Drug: D326(placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 1 tablet once a day for 8 weeks
Study: NCT04388215
Drug: D337(placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 1 tablet once a day for 8 weeks
Study: NCT04388215
Drug: D013(placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 1 tablet once a day for 8 weeks
Study: NCT02168101
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg.
Study: NCT00088270
Drug: 5-Fluorouracil/Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00847899
Drug: AR9281
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR9281 taken in BID dosing regimen for 28 days
Study: NCT00847899
Drug: AR9281
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR9281 taken in TID dosing regimen for 28 days
Study: NCT00847899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken in BID dosing regimen for 28 days
Study: NCT00847899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken in TID dosing regimen for 28 days
Study: NCT01799057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
Study: NCT03813875
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
Study: NCT01440114
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
Study: NCT01378650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo one tablet matching for cilostazol twice a day for 4 weeks.
Study: NCT01127984
Drug: tissucol
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
Study: NCT04608110
Drug: ASTX030
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
Study: NCT00903279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
Study: NCT01057693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as capsules and given 3 times daily.
Study: NCT01804049
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
Study: NCT03443089
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
Study: NCT03443089
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
Study: NCT01457664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to RO4995819 once daily for 14 days
Study: NCT01457664
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO4995819 doses once daily for 14 days
Study: NCT01527240
Drug: Ciclosprin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
Study: NCT01527240
Drug: Injectable Saline Solution.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Solution is administered once 15 min after thrombolysis.
Study: NCT00568594
Drug: APL180
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01419600
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose Inhaled IMP via Turbuhaler
Study: NCT01419600
Drug: Placebo to match
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose Inhaled Placebo via Turbuhaler
Study: NCT04340388
Drug: Antiretroviral/Anti HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
Study: NCT01453491
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
Study: NCT00221546
Drug: Giving DHA-rich supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving DHA-rich supplement to patients.
Study: NCT03705559
Drug: Vaporized Marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Marijuana or Placebo, administered through vaporizer
Study: NCT03705559
Drug: Opioid Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Opioid Agonist or Placebo, administered intranasally
Study: NCT00681395
Drug: ABT-143
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 6 days
Study: NCT00681395
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for six days
Study: NCT00681395
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily for 6 days
Study: NCT01094977
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01833858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
Study: NCT00295282
Drug: MDX-1100 (anti-CXCL10 human monoclonal antibody)
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
Study: NCT02948582
Drug: Glycopyrrolate Inhalation Solution12.5μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
Study: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 50μg
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
Study: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 100μg
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
Study: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 200μg
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
Study: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 400μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
Study: NCT02948582
Drug: Placebo 0.5mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5mL via eFlow, once daily
Study: NCT00334568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01925768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
Study: NCT01308359
Drug: IV glucose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml glucose 5% within 30 minutes
Study: NCT00004891
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02967679
Drug: MD1003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02985177
Drug: INF2.0 + IBU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics
Study: NCT02985177
Drug: INF1.0 + IBU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics
Study: NCT00473876
Drug: Matched Placebo (Capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar dosing regime as active comparator
Study: NCT02168595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00124280
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01818726
Drug: ICL670
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
Study: NCT01818726
Drug: Chelation
Normalized name: MULTIVIT/MIN, HERBAL CHELATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
Study: NCT01818726
Drug: No chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
Study: NCT01918865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02452385
Drug: CM082 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM082 tablets taken orally
Study: NCT02015949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily placebo tablet for two weeks
Study: NCT01299467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
Study: NCT00583674
Drug: AMG 386 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Study: NCT00583674
Drug: AMG 386 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Study: NCT00583674
Drug: AMG 386 3mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Study: NCT00583674
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Study: NCT00583674
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Study: NCT03522415
Drug: Methotrexate（MTX）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate is a slow-acting antirheumatic drug.
Study: NCT00935493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo po qhs
Study: NCT01119066
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
Study: NCT03936907
Drug: OWCP Orally Disintegrating Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
Study: NCT03139032
Drug: APD334
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD334 active treatment for 12 weeks.
Study: NCT00742131
Drug: GSK1363089
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
Study: NCT03794440
Drug: IBI305
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg IV d1， Q3W
Study: NCT00635141
Drug: hypertonic saline (7 %) and isotonic saline (0.9%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Study: NCT00635141
Drug: hypertonic saline (7 %) and isotonic saline (0.9%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Study: NCT01442337
Drug: ASP8597
Approvals — FDA: no, EMA: no, PMDA: no
Description: one time IV dose
Study: NCT01442337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one time IV dose
Study: NCT02804633
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram every 6 hours
Study: NCT02804633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of normal saline every 6 hours
Study: NCT00894699
Drug: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
Study: NCT00894699
Drug: Placebo NanoTab™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of sublingual placebo NanoTab™
Study: NCT00525668
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
Study: NCT01905475
Drug: POL6326
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01905475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05567523
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT02243371
Drug: CY
Normalized name: CYT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
Study: NCT02289365
Drug: 3000 mg of PEG-400 per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
Study: NCT02284256
Drug: Fibrocaps
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001335
Drug: ADR-529
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02941328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
Study: NCT02263872
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 200mg perday
Study: NCT01720303
Drug: isophane human insulin
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection s.c. (under the skin) at bedtime